Subcapsular sinus macrophages limit dissemination of West Nile virus particles after inoculation but are not essential for the development of West Nile virus-specific T cell responses  by Winkelmann, Evandro R. et al.
Subcapsular sinus macrophages limit dissemination of West Nile virus
particles after inoculation but are not essential for the development
of West Nile virus-speciﬁc T cell responses
Evandro R. Winkelmann a, Douglas G. Widman b,1, Jingya Xia b, Alison J. Johnson b,2,
Nico van Rooijen c, Peter W. Mason a,3, Nigel Bourne d,e, Gregg N. Milligan b,d,e,n
a Department of Pathology, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA
b Department of Microbiology and Immunology, UTMB, Galveston, TX, USA
c Vrije Universiteit, Amsterdam, The Netherlands
d Department of Pediatrics, UTMB, 301 University Boulevard, Galveston, TX 77555-0436, USA
e Sealy Center for Vaccine Development, UTMB, Galveston, TX 77555-0436, USA
a r t i c l e i n f o
Article history:
Received 5 August 2013
Returned to author for revisions
27 August 2013
Accepted 17 December 2013
Available online 10 January 2014
Keywords:
West Nile virus
Single-cycle ﬂavivirus
RepliVAX
subcapsular sinus macrophages
CD8þ T cell
a b s t r a c t
Macrophages encounter ﬂaviviruses early after injection by arthropod vectors. Using in vivo imaging of mice
inoculated with ﬁreﬂy luciferase-expressing single-cycle ﬂavivirus particles (FLUC-SCFV), we examined the
initial dissemination of virus particles in the presence or absence of lymph node (LN)-resident macrophages.
Higher luciferase activity, indicating higher SCFV gene expression, was detected in the footpad of macrophage-
depleted mice after 24 h post infection (hpi). Moreover, FLUC-SCFV particles disseminated to the spleen within
14 hpi in macrophage-depleted, but not control mice. Although macrophages presented SCFV to naïve T cells
in vitro, depletion of subcapsular sinus (SCS) macrophages did not alter the magnitude or effector function of
the WNV-speciﬁc CD8þ T cell response. Together, these results indicate that SCS macrophages play a role in
limiting the dissemination of SCFV early in infection but are not required for the generation of a polyfunctional
WNV-speciﬁc CD8þ T cell response in the draining LN.
& 2014 Elsevier Inc. All rights reserved.
Introduction
West Nile virus (WNV) is a member of the Flavivirus genus of
the family Flaviviridae. Flaviviruses have an 11 kb single-stranded,
positive sense RNA genome with a single open reading frame
encoding three structural proteins (C, prM/M and E) and seven
non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and
NS5) (Lindenbach et al., 2007). WNV exists in nature in an enzootic
life cycle involving transmission between mosquitoes and birds.
Transmission to mammals including humans occurs by the feeding
of infected mosquitoes and does not result in further transmission.
Infection of humans results in disease ranging from asymptomatic
to neurological including the development of meningitis, ence-
phalitis, and occasionally mortality (Campbell et al., 2002).
Recently, we reported the development of single-cycle ﬂaviviruses
(SCFV) that can be utilized as safe and effective vaccines (Mason et al.,
2006). This single-cycle technology has been used to produce a series
of ﬂavivirus vaccine candidates (named RepliVAX), that encode
ﬂavivirus genomes harboring a truncated C (trC) gene that prevents
the RepliVAX genome from being packaged into infectious particles
unless the C gene is supplied in trans (Ishikawa et al., 2008; Mason
et al., 2006; Suzuki et al., 2009; Widman et al., 2008b). The RepliVAX
WN particle can initiate a single round of infection in normal cells.
These infected cells release prM/E-containing sub-viral particles (SVPs)
and the nonstructural protein NS1 that have been shown to induce
effective antiviral immune responses (Chung et al., 2007; Diamond
et al., 2008; Roehrig et al., 2001; Widman et al., 2008a, 2008b).
RepliVAXWN-infected cells cannot produce progeny virus in vivo, thus
making RepliVAX WN a safe, live-attenuated vaccine. Because the
early events of infectionwith RepliVAXWN occur as they do following
inoculation of a wild-type virus, RepliVAX WN serves as a useful
model to study the early host response to ﬂavivirus infection including
initiation of the innate immune response and recognition of SCFV
particle-encoded viral antigens.
Innate immunity to West Nile virus is initiated following recogni-
tion by the pattern recognition receptors TLR3 (Wang et al., 2004),
TLR7 (Welte et al., 2009), RIG-I, or MDA5 (Fredericksen et al., 2008).
Innate immune responses play an essential role in controlling the early
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stages of viral infection. Beyond the interferon (IFN)-induced cell-
intrinsic responses that limit initial viral replication, innate immune
cells such as neutrophils and γδ T cells are known to play a role in host
protection by controlling virus infection through direct lysis of virus-
infected cells or by production of cytokines (Bai et al., 2010; Wang
et al., 2003). The role of natural killer (NK) cells inWNV infection is not
completely understood. NK cell activating receptor NKp44 interacts
directly with WNV envelope protein resulting in NK cell activation,
production of IFN-γ and expression of cell-lytic properties
(Hershkovitz et al., 2009). Although not required for modulating
WNV infection in the spleen, a role for NK cells in controlling WNV
infection in the liver is suggested by the upregulation of NK signal
pathway gene expression in the liver after WNV infection (Suthar
et al., 2013). Macrophage populations are present at peripheral sites as
well as in draining LN and therefore may also play a direct role in
limiting infection or dissemination of virus through the lymphatics
during the initial stages of infection. Additionally, macrophages may
play a role in activation or shaping of the adaptive immune response
through presentation of viral antigen to antigen-speciﬁc cells and the
secretion of proinﬂammatory cytokines/chemokines at the site of
infection and in the draining lymph nodes. However, the role of
macrophages in limiting virus dissemination and induction of WNV-
speciﬁc T cell responses is not completely understood.
Activation and development of the WNV-speciﬁc CD8þ T cell
response is complex and involves the interaction of many cytokines
and signaling pathways including type I IFN (Pinto et al., 2011;
Winkelmann et al., 2012), CD22 (Ma et al., 2013), MDA5 (Lazear
et al., 2013), interferon regulatory factor-1 (Brien et al., 2011) and
interferon promoter stimulator-1 (Suthar et al., 2010). Early studies
demonstrated that macrophages, B cells and dendritic cells (DC) were
capable of serving as antigen presenting cells for WNV-speciﬁc T cell
responses (Kulkarni et al., 1991). However, more recent studies have
demonstrated a dominant role for CD8αþ DC in activation of WNV-
speciﬁc CD8þ T cell subsets in vivo (Hildner et al., 2008). Interestingly,
subcapsular sinus (SCS) macrophages of regional lymph nodes have
been shown to play a role in the development of the B cell response to
vesicular stomatitis virus (Carrasco and Batista, 2007; Junt et al., 2007),
in invariant NKT cell activation (Barral et al., 2010), and recently in
antigen presentation and early activation of the acquired immune
response (Martinez-Pomares and Gordon, 2012). While SCS macro-
phages are not required for a developing B cell response (Purtha et al.,
2008), the role these cells play in development of CD8þ T cell
responses to WNV is not fully known.
In the studies presented here, we utilized clodronate-liposome
depletion of SCS macrophages from lymphoid tissue draining the site
of inoculation with the SCFV particle to examine the role of these cells
in controlling the initial infection and dissemination from the site of
inoculation. Furthermore, we examined the role of SCS macrophages
as antigen-presenting cells in the initiation of the virus-speciﬁc CD8þ
T cell response. We report that depletion of SCS macrophages from the
draining LN results in a diminished ability to conﬁne the initial spread
of virus at very early times post infection. Additionally, we demon-
strate that SCS macrophages are not required for activation of the cell-
mediated arm of the adaptive immune response in the draining LN
and provide evidence for the antigen-presenting function of speciﬁc
dendritic cell (DC) subsets from RepliVAXWN-infected mice. Together,
these results further illuminate the role of SCS macrophages in
protection against WNV during the early stages of infection.
Results
SCS Macrophages limit SCFV dissemination and SCFV gene expression
Tissue resident macrophages are present at sites of pathogen
entry and play important roles in the innate immune response
against many viral pathogens. To study the biological function of
macrophages in the initial stages of a WNV infection, we depleted
mice of macrophages in the draining lymph nodes by subcuta-
neous inoculation of hind footpads (FP) with clodronate-
containing liposomes (CCL) (Delemarre et al., 1990) prior to FP
inoculation of SCFV (Fig. 1A). To conﬁrm CCL-mediated depletion
from draining lymph nodes, cells from the popliteal LN (pLN),
inguinal LN (ingLN) and spleens were harvested 7 days after
injection of CCL or PBS-loaded liposomes (PBSL) into the hind FP
and analyzed for expression of the macrophage surface markers,
integrin αM chain (CD11b) and F4/80, or the SCS macrophage-
expressed protein CD169, by ﬂow cytometry. Additionally, lym-
phoid cells were tested for depletion of dendritic cells by staining
for expression of the integrin αX chain (CD11c). As expected, mice
treated with CCL were depleted of CD169þ CD11c cells and, to a
lesser extent, F4/80þ CD11bþ cell populations in the pLN, corre-
sponding to SCS and medullary macrophages, respectively (Fig. 1B
and C). CCL treatment did not deplete macrophages from the
ingLN. Additionally, consistent with reports by others (Delemarre
et al., 1990; Purtha et al., 2008), FP administration of CCL did not
deplete macrophage populations from the spleen. As shown in
Fig. 1D, treatment of mice with CCL did not result in signiﬁcant
reduction of dendritic cells (CD11bþ , CD11cþ) from any of the
lymphoid tissues tested.
Macrophages can function in protection through direct clear-
ance of viral particles and evidence from depletion studies by
others suggests that they are essential to control systemic WNV
infection and limit inﬁltration of virus into the central nervous
system (Ben-Nathan et al., 1996). However, it is not clear from
these studies if macrophages play a role in control of the initial
dissemination of virus from the site of inoculation or provide
protection only at later stages of infection. Assessing control of
dissemination of the initial viral inoculum is complicated by the
presence of continuous virus replication and new rounds of
infection. Therefore, we visualized the initial dissemination of
FLUC-SCFV from the FP in control-treated and macrophage-
depleted mice using an in vivo imaging system (IVIS). Groups of
B6 mice received PBSL or CCL, were inoculated in the hind FP with
FLUC-SCFV, and imaged at intervals between 14 and 48 h post-
inoculation (hpi). SCFV-encoded FLUC gene expression was quan-
tiﬁed at the FP site of infection, draining LN and spleen. As shown
in Fig. 2, luciferase bioluminescence was detected in the FP of all
CCL- and PBSL-treated mice at 14 hpi, and by 24 hpi differential
expression of FLUC was detected in the FP and lymphoid tissues of
macrophage-depleted and control mice.
The results of IVIS analysis of FLUC-SCFV dissemination to
speciﬁc tissues are shown in graphic form in Fig. 3. Expression of
FLUC-SCFV genes was readily detected in the hind FP of all FLUC-
SCFV-infected mice. At 14 hpi, FLUC gene expression at this site
was detected at similar levels in the CCL- and PBSL-treated groups.
However, expression increased approximately 10-fold in the CCL-
treated mice and was signiﬁcantly higher than expression in PBSL-
treated mice at all time points from 24–48 hpi (po0.001, Fig. 3A).
Lymphatic drainage of the hind FP of mice involves both the pLN
and ingLN (Harrell et al., 2008). The luciferase bioluminescence
detected in the pLN of CCL- and PBSL-treated mice was nearly
equivalent at 14 hpi and was absent in both mouse groups by
36 hpi. Interestingly, at 24 hpi FLUC gene expression was detected
in all PBSL-treated mice but in only 2 of 10 pLN in macrophage-
depleted mice although at a signiﬁcantly higher expression level
(po0.01) (Fig. 3B). In the ingLN, luciferase bioluminescence was
detected in 5 of 8 in PBSL-treated mice at 14 hpi and expression
decreased thereafter such that FLUC activity was detected at
low levels in only 1 of 8 ingLN at 48 hpi. By contrast, FLUC
gene expression was signiﬁcantly higher at 14 hpi in the
ingLN of CCL-treated group (po0.01), and remained higher at
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the 24, 36, and 48 h time points (Fig. 3C). A greater frequency of
CCL-treated mice expressed FLUC activity in the ingLN at both 36
and 48 hpi: 7 of 10 compared to 3 of 8 in PBSL-treated mice at
36 hpi and 6 of 10 compared to 1 of 8 in PBSL-treated mice at
48 hpi (Fig. 3C). Luciferase bioluminescence was not detected at
any time point in the spleens of PBSL-treated mice although it was
detected at high level in all CCL-treated mice at 14 hpi (po0.001,
Fig. 3D).
Higher serum IFN-α level in SCS macrophage-depleted mice
Type I IFN are produced by many cells types and have a critical
function as an initial mechanism to prevent virus infection through
their antiviral effects. To investigate the effects of SCS macrophage
depletion at the regional site of infection on systemic production of
type I IFN, wemeasured the amount of IFN-alpha (IFN-α) and IFN-beta
(IFN-β) in the serum of mice at 24 hpi. Interestingly, the serum level of
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Fig. 1. Macrophage depletion after subcutaneous FP injection of CCL. Seven days post injection, cells from the spleen, pLN and ingLN were analyzed for the expression of
CD11b, CD11c, F4/80 and MOMA-I (CD169) by ﬂow cytometry. (A) Schematic showing lymphatic drainage from the footpad. The percentage of (B) CD169þ CD11c cells (SCS
macrophages), (C) CD11bþ F4/80þ cells (medullary macrophages) or CD11bþ , CD11cþ (dendritic cells) from CCL- or PBSL-treated mice are shown. Error bars indicate
standard deviation (3 mice per group). P value determined by Student0s t test.
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IFN-α was two-times higher in the macrophage-depleted group
(po0.0001) (Fig. 4). IFN-β was not detected in any treatment group.
This result is consistent with our previous report showing that IFN-β is
produced at low levels in mice inoculated with a single-cycle ﬂavivirus
(Bourne et al., 2007). Cytokines and chemokines were quantiﬁed in
the sera of RepliVAX WN-inoculated mice at 14, 24, 48, 72, 120, and
168 hpi. As shown in Fig. 5, serum levels of IL-1β, IL-6, CCL2, CCL4, and
CCL5 peaked at 14 hpi in both CCL- and PBSL-treated mice and
declined precipitously thereafter. Serum levels of IL-12p70, and TNF-
α remained at baseline levels until 72 hpi before rising through
168 hpi. Levels of IL-6 and CCL2 were signiﬁcantly higher at 14 and
24 hpi in CCL-treated compared to PBSL-treated mice. However, for IL-
1β, IL-12p70, TNF-α, CCL4, and CCL5 the pattern and quantity of
cytokines and chemokines produced following RepliVAX WN FP
inoculation were not different between CCL- and PBSL-treated mice.
SCS macrophages are not required to initiate a WNV-speciﬁc CD8þ
T-cell response in the draining LN
Beyond phagocytosis of viral particles and production of
cytokines, macrophages can serve as potent antigen-presenting
cells (APC) and may therefore play a critical role in presenting
Macrophage-depleted –14 hpi Control –14 hpi
Macrophage-depleted – 24 hpi Control – 24 hpi
Fig. 2. Role of SCS macrophages in limiting the dissemination of SCFV. CCL- or PBSL-treated B6 mice were inoculated subcutaneously in both hind FP with 107 IU of FLUC-
SCFV on day 7 after liposome injection. Mice were imaged at 14, 24, 36 and 48 hpi. Representative images of mice at 14 hpi and 24 hpi.
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WNV antigen to and activating naive WNV-speciﬁc T cells in
draining LN. To examine the requirement for SCS macrophages
to initiate the WNV-speciﬁc CD8þ T cell response, mice were CCL-
or PBSL-treated prior to inoculation with FLUC-SCFV. As shown in
Fig. 6, the number of IFN-gamma (IFN-γ)-secreting cells speciﬁc
for the immunodominant CD8þ T cell epitope of the NS4B protein,
NS4B2488, was not different in the spleen or draining LN between
PBSL-treated and CCL-treated mice. These data suggest that
SCS macrophages are not required for development of the cell-
mediated response. This result is not due to an inability of
macrophages to present virus-derived epitopes as bone marrow-
derived macrophages (BM-MØ) infected with gB/OVA-RepliVAX
WN efﬁciently presented virus-expressed ovalbumin SIINFEKL
epitope to naïve OVA-speciﬁc OT-I T cells resulting in T cell
proliferation (Fig. 7A). These results suggest that other cells, such
as DC most likely served as the APC in macrophage-depleted mice.
Consistent with this notion, co-culture of naïve OT-I T cells and
bone marrow-derived DC (BM-DC) infected with gB/OVA-Repli-
VAX WN also resulted in T cell replication (Fig. 7B). Additionally,
DC isolated from the spleens of gB/OVA-RepliVAX WN-infected
mice were also capable of presenting antigen to naïve OT-I T
cells. Two major populations of spleen DC have been described;
CD11b CD8αþCD11cþ and CD11bþ CD8α CD11cþ (Anjuere
et al., 1999). OVA-speciﬁc T cell proliferation was observed follow-
ing culture with either CD11bþ CD8α CD11cþ (Fig. 7C) or
CD11b CD8αþ CD11cþ (Fig. 7D) DC subsets isolated on day
3 post inoculation, consistent with the role of these cells as
professional APC.
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Fig. 3. Magnitude of SCFV gene expression in vivo in SCS macrophage-depleted and control-treated B6 mice. Images were taken at the indicated time points and
bioluminescence was observed using up to 90 s exposures at medium binning. The total ﬂux emanating from each region of interest (ROI) was measured for the indicated
tissues from each mouse group. Each point represents the measurement of one ROI (in the cases of FP and LN, two per animal) and the line represents the average of all site
per group (macrophage-depleted, n¼5; control group, n¼4) above the limit of detection (LOD). nnpo0.01, nnnpo0.001, two-way ANOVA, Bonferroni post test.
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We considered the possibility that SCS macrophages played a
role in determining the quality of the CD8þ T cell response. The
polyfunctionality of WNV-speciﬁc effector CD8þ T cells was
measured as the ability to simultaneously produce IFN-γ, TNF-α,
and IL-2. As shown in Fig. 8A, cytokines were produced as a result
of stimulation of CD8þ T cells from RepliVAX WN-inoculated mice
with the peptide representing the immunodominant epitope from
the NS4B protein, but not following stimulation with an irrelevant
peptide or medium only. Both the frequency and total number of
CD8þ T cells producing IFN-γ only, IFN-γþTNF-α, or IFN-γþTNF-
αþ IL-2 were very similar between spleen cells (Fig. 8B, C, F, G) or
pLN cells (Fig. 8D, E, H, I) from PBSL-treated and CCL-treated mice
on both day 5 and day 7 post inoculation. The only exceptions
were that signiﬁcantly higher numbers of spleen cells producing
IFN-γþTNF-α were detected on day 5 and the frequency of pLN
cells secreting only IFN-γ reached signiﬁcance on day 5. The
presence of these cytokine producing cells is likely responsible
for the high serum concentration of TNF-α (Fig. 5) and IFN-γ (data
not shown) at 120 and 168 hpi. In total, these data indicate that
depletion of SCS macrophages had little effect on the development
of CD8þ T cell effector function in the draining LN following
RepliVAX WN inoculation.
Discussion
Tissue macrophages play a key role in maintaining homeostasis
through phagocytosis and removal of pathogens and cellular
debris and they represent one of the ﬁrst immune cells to
encounter virion particles following injection of arboviruses into
a mammalian host. Macrophages can be productively infected
with WNV (Kyle et al., 2007; Prestwood et al., 2012) although viral
replication is controlled by downstream effects of type I IFN
mediated in part by innate intrinsic protective mechanisms invol-
ving IRF-1, PKR, and RNase L (Brien et al., 2011; Kong et al., 2008;
Lazear et al., 2011; Samuel et al., 2006). Because of the highly
phagocytic nature of tissue macrophages, it is generally assumed
that these cells play a role in limiting the initial spread of virus
from the site of infection. This may occur through direct phago-
cytosis and destruction of virion particles or through elicitation of
immune reactive molecules that initiate the inﬁltration and
activation of a variety of innate host cells. This notion has been
tested in several studies of ﬂavivirus infection by assessing virus
titers in peripheral and neuronal tissues following selective
depletion of macrophages from the site of infection and from
draining LN. Depletion of macrophages prior to infection with
WNV (Ben-Nathan et al., 1996; Purtha et al., 2008) resulted in
periods of extended viremia with elevated levels of virus culmi-
nating in enhanced virus inﬁltration of the central nervous system
and accelerated development of encephalitis. Similar ﬁndings
were reported in a murine model of dengue virus infection (Fink
et al., 2009). Macrophages are involved in the orchestration
of early innate immune events as well as the activation and
inﬂuence on the adaptive immune system and therefore these
effects on ﬂavivirus infection in macrophage-depleted animals
may reﬂect loss of one or several critical functions. The use of
single-cycle WNV particles allowed us to focus on the role
of macrophages in the initial infection as well as on downstream
effects on activation of the adaptive immune response. The results
of the present study extend previously reported ﬁndings
(Ben-Nathan et al., 1996; Purtha et al., 2008), by demonstrating
that SCS macrophages act as a natural ﬁlter to limit virus
dissemination early after initial infection. Depletion of SCS macro-
phages from pLN resulted in spread of the FLUC-SCFV to the spleen
within the ﬁrst 14 h after infection. Additionally, luciferase biolu-
minescence was detected at increased levels at the FP in
these mice suggesting that tissue macrophages eliminated FLUC-
SCFV particles (or infected cells) and limited the infection at the
site of inoculation. Although macrophages can produce type
I IFN in response to infection with WNV SCFV particles, this early
resistance most likely did not involve type I IFN as serum levels
of IFN-α were approximately 2-fold higher in SCS macrophage-
depleted mice. These results suggest type I IFN production was
not macrophage-dependent and are consistent with production
of high levels of type I IFN by alternative cell types, such
as plasmacytoid DC (Swiecki and Colonna, 2010). Similarly,
serum levels of IL-6 and CCL2 were also higher at early time
points in macrophage-depleted animals suggesting that produc-
tion of these cytokines may be driven by the higher levels of virus
gene expression in CCL-treated mice. However, depletion of SCS
macrophages had no discernible effect on serum levels of IL-1β,
CCL4, CCL5 IL-12p70, and TNF-α following RepliVAX WN
inoculation.
Lymph which drains from body tissues enters the regional LN
through the afferent lymphatics and empties initially into the SCS.
Numerous macrophages have been shown to line both the sub-
capsular and medullary sinuses of the LN. A population of SCS
macrophages expressing CD169 has been shown to play a critical
role in capture and removal of virus particles from the lymph and
to prevent hematogenous virus spread (Junt et al., 2007). This
ﬁltration function was shown to occur as early as 2 h post
inoculation with vesicular stomatitis virus (VSV) and was required
for efﬁcient passage of virion antigen from the SCS to LN B cells
located in superﬁcial follicles (Junt et al., 2007). Subsequent
studies by Purtha et al. (2008) found that SCS macrophages were
not required for early B cell activation and development of the
WNV-speciﬁc antibody response. In addition to the role of SCS
macrophages in the development of B cell response (Carrasco and
Batista, 2007; Junt et al., 2007) and iNKT cell activation (Barral
et al., 2010), recent evidences also demonstrate the function of this
cell population in antigen presentation and early activation of the
acquired immune response (Martinez-Pomares and Gordon, 2012).
The results of the present study extend these ﬁndings by examin-
ing the requirement of SCS macrophages in activation of the WNV-
speciﬁc CD8þ T cell response in the draining LN. In agreement
with reports by others (Kulkarni et al., 1991), both SCFV-infected
macrophages and DC presented antigen to antigen-speciﬁc T cells.
Importantly, our results demonstrate that SCS macrophages in the
draining pLN were not required for induction of an antigen-
speciﬁc CD8þ T cell response or for development of effector T cell
function. This function was likely provided by DC and our results
further show that both CD11bþ CD8α CD11cþ and CD11b
CD8αþ CD11cþ DC subsets isolated from spleens of WNV SCFV
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Fig. 4. Serum levels of IFN-α in SCS macrophage-depleted and control-treated B6
mice. Sera were collected at 24 h post-infection from the mice described in Fig. 3
and the IFN-α concentrationwas determined by ELISA. A mock-infected CCL-treated
mouse was included as an additional control. Each point represents the IFN-α levels
of each mouse and the line represents the average per group of mice.
nnnnpo0.0001, Student0s t test.
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particle inoculated mice were capable of presenting virus-encoded
antigen to naïve T lymphocytes.
Taken together, the results of this study demonstrate that SCS
macrophages play an active role in limiting dissemination of virus
from the site of entry to the spleen at very early times after
inoculation. Tissue macrophages act at the site of inoculation and
reduce infectious load while SCS macrophages in the draining LN
act to prevent spread through the lymphatics and ultimately into
the spleen. Although SCFV-infected macrophages are capable of
presenting antigen to and activating naïve CD8þ T cells, SCS
macrophages are apparently not essential for initiating the cell-
mediated immune response or for development of effector T cell
function. These results extend previous results suggesting a role
for macrophages in preventing entry of WNV into the central
nervous system and clarify the role for this important innate
immune cell in the early stages of infection.
Materials and methods
Mice
Seven-week-old B6 mice were purchased from The Jackson
Laboratories (Bar Harbor, ME). T cell receptor (TCR) transgenic OT-
I mice (Falk et al.,1993) were bred onto a Thy1.1 background and
maintained as a breeding colony at the AAALAC-approved Animal
Resources Center at the University of Texas Medical Branch (UTMB).
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Fig. 5. Serum levels of selected cytokines and chemokines in SCS macrophage-depleted and control-treated B6 mice. Mice were inoculated in the FP with 107 IU of RepliVAX
WN and sera were collected at 14, 24, 48, 72, 120, and 168 hpi and assayed for the indicated cytokines and chemokines. The results represent the mean response of 3 mice/
group (n po0.05, nn po0.01, nnn po0.001, Two-way ANOVA).
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All animal work was approved by the Institutional Animal Care and
Use Committees of with oversight of staff veterinarians.
Cells
Vero cells were maintained in Dulbecco0s Modiﬁed Eagle0s
Medium (DMEM) (Cellgro, Mediatech, Manassas, VA) containing
6% fetal bovine serum (FBS) (HyClone, Thermo Scientiﬁc, Logan,
UT), 100 U/mL penicillin, 100 μg/mL streptomycin (GIBCO, Invitro-
gen, Grand Island, NY) and 20 μg/mL Gentamicin (Cellgro). BHK
(VEErep/Pac-Ubi-Cn) expressing the WNV C protein (Widman
et al., 2008b) and BHK(VEErep/WNVCn-E/Pac) cells expressing
the WNV C-prM-E proteins (Fayzulin et al., 2006) were propagated
in DMEM supplemented with 10% FBS and 10 μg/ml puromycin
(Cellgro) as previously described (Fayzulin et al., 2006).
Production of RepliVAX WN and related WNV-SCFV particles
RepliVAX WN and the gB/OVA-RepliVAX WN which encodes
the epitopes recognized by OT-I and gBT-I CD8þ T cells (ovalbumin
OVA257-264 [SIINFEKL] and HSV gB498-505 [SSIEFARL], respectively)
(Hogquist et al., 1994; Mueller et al., 2002) inserted into the
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Fig. 6. SCS macrophages are not required for the development of the WNV-speciﬁc CD8þ T cell response in the draining LN. SCS macrophage-depleted and control B6 mice
were inoculated with 107 IU of FLUC-SCFV at day 7 after liposome injection. The two pLN were pooled for individual animals (A) and spleens (B) were harvested at day 7 post
infection and cells were used for quantiﬁcation of the number of IFN-γ-secreting cells (IFN-γ SC) speciﬁc for the WNV NS4B2488 CD8þ T cell epitope by ELISPOT. Each point
represents the number of IFN-γ SC from pooled LN of individual mice and the line represents the mean per group of mice. Data are representative of two independent
experiments.
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Fig. 7. Ability of macrophages and dendritic cells to stimulate CD8þ T cell proliferation. Serial dilutions of BM-MØ (A) and BM-DC (B) infected with gB/OVA-RepliVAX WN at
a MOI of 100 were co-cultured with constant numbers of naïve OT-1 CD8þ T cells for 72 h (see material and methods). Bars represent proliferation of T cells measured by
CFSE signal dilution. Error bars represent standard deviation of duplicates or triplicates from each dilution. (C) and (D) B6 mice were immunized with 2107 IU gB/OVA-
RepliVAX WN. On day 3, cells from spleen were harvested and CD11bþ CD8α CD11cþ (C) and CD11b CD8αþ CD11cþ (D) DC subpopulations were sorted by ﬂow
cytometry and co-cultured with naïve CD8þ T cells from OT-I mice as described above (see also materials and methods). Bars represent proliferation of T cells measured by
CFSE signal dilution and error bars represent standard deviation of two independent experiments.
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Fig. 8. Cytokine production by WNV-speciﬁc CD8þ T lymphocytes is not affected by depletion of SCS macrophages. CCL- or PBSL treated B6 mice (n¼6) were inoculated in
the FP with 107 IU RepliVAX WN. Lymphocytes from spleen and pLN were harvested on day 5 (n¼2) or day 7 pi (n¼4), stimulated and assayed for production of cytokines as
described in methods. (A) Representative staining for IFN-γ and TNF-α in splenocytes stimulated with NS4B peptide, irrelevant peptide, or medium. The mean (7 SD)
frequency (B, D, F, H) or total cell number (C, E, G, I) of cytokine producing CD8þ T cells from the spleen or pLN are shown (npo0.05).
E.R. Winkelmann et al. / Virology 450-451 (2014) 278–289286
truncated capsid gene of WNV (Fig. S1) were produced in BHK
(VEErep/Pac-Ubi-Cn) cells as described previously (Widman et al.,
2008b). FLUC-SCFV were produced in BHK (VEErep/Cn-prM-E-Pac)
cells as described previously (Gilfoy et al., 2009). Infectious titers
(IU/ml) of RepliVAXWN and WNV SCFV particles were determined
on Vero cells as previously described (Fayzulin et al., 2006).
Depletion of macrophages by injection of clodronate liposomes
To deplete macrophages from the regional draining LN of B6
mice, 20 μl of a suspension of CCL containing 5 mg/ml clodronate
(a gift of Roche Diagnostics GmbH, Mannheim, Germany) or
control PBSL was injected subcutaneously in each FP 7 days before
SCFV inoculation. CCL and control PBSL were prepared as pre-
viously described (van Rooijen and Sanders, 1994). To conﬁrm the
depletion, cells from spleen, pLN and ingLN were stained with
ﬂuorochrome-conjugated mAb anti-CD11c (PE) (BD Biosciences,
San Jose, CA), -F4/80 (APC) (AbD Serotec, Raleigh, NC), -CD11b
(FITC) (BD Biosciences) or -MOMA-1 (CD169) (FITC) (AbD Serotec)
and data were acquired on a BD LSRII Fortessa and analyzed using
FlowJo software (Tree Star, Ashland, OR).
In vivo imaging
Mice were inoculated subcutaneously in both hind FP with FLUC-
SCFV (Gilfoy et al., 2009) at a dose of 107 IU/FP 7 days after CCL or
PBSL treatment. Prior to inoculation, the posterior half of all animals
were shaved to facilitate the acquisition of luciferase signal. Mice
were imaged at 14, 24, 36 and 48 hpi. At each time point, mice were
injected intraperitoneally with a D-luciferin solution (Caliper LS,
Hopkinton, MA) corresponding to the dose of 15 mg/kg body weight.
After 20 min to allow D-luciferin distribution, mice were anesthe-
tized with 90 mg/kg ketamine and 8 mg/kg xylazine, and real-time
in vivo imaging was performed using a Xenogen IVIS 200 (Caliper LS)
with exposure times ranging from 1 to 90 s at medium binning. The
images were analyzed using the Living Image 4.0 software (Caliper
LS), where the total ﬂux from each region of interested (ROI) was
measured and reported as photons per second (photons/s). The limit
of detection of the luciferase signal was considered to be
104 photons/s of each ROI analyzed.
Interferon and cytokine detection
Type I interferon was quantiﬁed using commercial IFN-α and
IFN-β ELISA kits (PBL Biomedical Laboratories, Piscataway, NJ),
following the manufacturer0s protocol. The limit of detection for
the assays was 12.5 pg/ml. Cytokine and chemokine levels in the
sera of individual RepliVAX WN-inoculated mice were determined
using a luminescence-based multiplex bead assay (Bio-Rad, Her-
cules, CA) from a panel of 23 cytokines following the man-
ufacturer0s protocols as performed previously (Winkelmann
et al., 2012).
Enzyme-linked immunospot assay (ELISPOT).
ELISPOT assays were performed as previously described
(Nelson et al., 2010) using microtiter ﬁlter plates (Millipore, Bill-
erica, MA) coated with puriﬁed anti-mouse IFN-γ monoclonal
antibody (BD Pharmingen) and incubated at 4 1C overnight. Serial
dilutions of splenocytes and pooled pLN cells from individual CCL-
and PBSL-treated mice were plated and stimulated with an
immunogenic peptide representing the WNV-speciﬁc CD8þ T
cell epitope (NS4B2488) (Brien et al., 2007; Purtha et al., 2007).
After 40 h incubation, plates were developed with biotinylated
anti-mouse IFN-γ (BD Pharmingen) and streptavidin-peroxidase
(Sigma-Aldrich, St. Louis, MO) and the number of spots in each
well, representing the number of IFN-γ secreting cells (SC), were
quantiﬁed using an ImmunoSpot reader and analyzed with Immu-
noSpot software (Cellular Technology Ltd, Cleveland, OH). The
total number of IFN-γ secreting cells were calculated and
expressed as IFN-γ SC per spleen or pLN.
Intracellular cytokine staining
Lymphocytes from spleens and pLN from CCL- or PBSL-treated
mice were harvested on day 5 or 7 after RepliVAX WN vaccination
and were re-stimulated with NS4B2488 peptide and stained for
IFN-γ, IL-2, and TNF-α as described previously (Winkelmann et al.,
2012). Data were acquired on a BD LSRII Fortessa (BD Biosciences)
and analyzed using FlowJo software (Tree Star). The total number
of cells secreting IFN-γ, IFN-γþTNF-α, or IFN-γþTNF-αþ IL-2 was
derived by multiplying the % of cells secreting a particular cytokine
combination by the total number of viable spleen or pLN cells.
Antigen presentation by DC subsets isolated from RepliVAX WN
infected mice
Three days after intraperitoneal inoculation of B6 with
2107 IU of gB/OVA-RepliVAX WN, splenocytes were harvested
and DC were enriched by depletion of B, T and NK cells using anti-
CD19, -CD90.2, -CD49 (DX5) microbeads (Miltenyi Biotec, Auburn,
CA), following the manufacturer0s protocol. Enriched cells were
then surface-stained with ﬂuorochrome-conjugated mAb anti-
CD8α (APC), -CD11c (PE) and -CD11b (PE-Cy7) (BD Biosciences)
and sorted into CD11bþ CD11cþ and CD8αþ CD11cþ subpopula-
tions using a BD FACS Aria. Serial 2-fold dilutions of CD11cþ
CD11bþ or CD11cþCD8αþ DC subpopulations were co-cultured
with 105 naïve OT-I T cells selected by using the CD8þ T cell
Isolation Kit II (Miltenyi Biotec) and labeled with 2 μM of carbox-
yﬂuorescein succinimidyl ester (CFSE) (Molecular Probes, Invitro-
gen) in 96-well plates. After 72 h, cells were surface-stained with
ﬂuorochrome-conjugated mAb anti-CD90.2 (PE) (BD biosciences),
data were acquired on a BD LSRII Fortessa, and the proliferation of
T cells measured as dilution of intracellular CFSE was determined
by using FlowJo software (Tree Star).
In vitro studies using BM-DC and BM-MØ
To generate BM-DC, femurs were aseptically collected, extra-
neous tissues were removed and then both ends of the bone were
cut to expose the lumen. Marrow cells were ﬂushed with 4 ml of
Hank0s Balanced Salt Solution (HBSS) (Sigma-Aldrich) containing
5% new born calf serum (NBCS) (GIBCO, Invitrogen) and 1%
penicillin/streptomycin using a 26-gauge needle and pushed
through a mesh screen to create a single-cell suspension. After
washing the cells once with HBSS, red blood cells were removed
using RBC lysis buffer (Sigma-Aldrich) and lymphocytes were
washed 3 times with HBSS and resuspended at the concentration
of 2106 cells/ml in culture medium [RPMI-1640 (Cellgro) sup-
plemented with 10% FBS, 1% penicillin/streptomycin and 1 mM
sodium pyruvate (Sigma-Aldrich)] containing 20 ng/ml of recom-
binant mouse granulocyte-macrophage colony-stimulating factor
(GM-CSF) (R&D Systems, Minneapolis, MN) and 20 ng/ml recom-
binant mouse IL-4 (BD Pharmingen). Cells were plated in 100 mm
cell culture dishes in a total 10 ml per dish and incubated for 10
days. On day 3, an additional 10 ml of medium was added to each
culture dish. On days 6 and 8, 10 ml of the medium was removed
without discarding any cells and fresh medium was added to the
culture dishes.
To generate BM-MØ, bone marrow cells were resuspended at
7105 cells/ml and plated in 100 mm non-treated culture dishes
in 10 ml of culture medium containing 100 ng/ml of recombinant
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mouse macrophage colony-stimulating factor (M-CSF) (PeproTech,
Rocky Hill, NJ) and incubated at 37 1C, 5% CO2 for 7 days. On day
3 an additional 5 ml of medium was added to each culture dish.
Infection of BM-DC and BM-MØ and co-culture with CD8þ T cells
BM-DC and BM-MØ were infected with gB/OVA-RepliVAX WN
at a multiplicity of infection (MOI) of 100 for 2 h at 37 1C. Cells
were washed 3 times with HBSS, resuspended in culture media
and incubated for an additional 24 h. Serial 2-fold dilutions of
infected BM-DC or BM-MØ were co-cultured with 105 naïve OT-I x
Thy1.1þ CD8þ T cells as described above. After 72 h, cells were
surface-stained with ﬂuorochrome-conjugated mAb anti-CD90.1
(PE) (BD Biosciences), data were acquired on a BD LSRII Fortessa,
and the proliferation of T cells was measured as dilution of
intracellular CFSE analyzed using FlowJo software (Tree Star).
Statistical analyses
GraphPad Prism (GraphPad Software, San Diego, CA) was used
to analyze data. Student0s t test, one-way or two-way analysis of
variance (ANOVA) with the Bonferroni post-test was used where
appropriate. P values less than 0.05 were considered to indicate
statistical signiﬁcance.
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